CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...

Citizens JMP lowered the firm’s price target on Relay Therapeutics (RLAY) to $12 from $21 and keeps an Outperform rating on the shares. Relay ...

The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

Our RLY-2608 breast cancer program continued to advance and develop rapidly in 2024, driven by positive maturation of the RLY-2608 + ...

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

today announced that the first patient has been dosed in a Phase I trial evaluating SNV4818 as a monotherapy and in combination with fulvestrant, in patients with breast cancer and other solid tumors.

The NDA is seeking approval for inavolisib in combination with Pfizer’s PFE Ibrance (palbociclib) and AstraZeneca’s AZN Faslodex (fulvestrant) to treat adult patients with PIK3CA-mutated ...